# Evaluation of SYS6005 in Patients With Advanced Malignant Tumor

> **NCT06958679** · PHASE1 · RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 132 (estimated)

## Conditions studied

- B-cell Malignancies
- Solid Tumors

## Interventions

- **DRUG:** SYS6005

## Key facts

- **NCT ID:** NCT06958679
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2027-01-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06958679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06958679, "Evaluation of SYS6005 in Patients With Advanced Malignant Tumor". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06958679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*